| Penulis/Author |
Irfan Haris (1); dr. Susanna Hilda Hutajulu, Ph.D. Sp.PD-KHOM (2) ; Yufi Kartika Astari (3); Juan Adrian Wiranata (4); Prof. Dr. dr. Irianiwati, Sp.PA.(K) (5); dr. Johan Kurnianda, Sp.PD-KHOM (6); Dr. dr. Kartika Widayati, SpPD-KHOM (7); dr. Mardiah Suci Hardianti, Ph.D. Sp.PD-KHOM (8); Prof. Dr. dr. Ibnu Purwanto, Sp.PD., K.HOM. (9); Prof. Dra. Raden Ajeng Yayi Suryo Prabandari, M.Si., Ph.D. (10) |
| Abstrak/Abstract |
Introduction
Sexual dysfunction is rarely studied in Indonesian patients with breast cancer. We aimed to assess the
prevalence of sexual dysfunction symptoms following chemotherapy, as well as the pattern and the
associated factors.
Methods
This cross-sectional study included 135 female breast cancer patients receiving primary chemotherapy. The
present study measured the prevalence of sexual dysfunction symptoms using an e-questionnaire
containing Common Toxicity Criteria for Adverse Events (CTCAE) version 4 at different time points. Other
data included sociodemography, clinicopathology, treatment, and other concurrent symptom
characteristics. Bivariate and multivariate logistic regression tests were used to analyze any association
among variables.
Results
In the whole panel, 86 (63.7%) of 135 cases experienced sexual dysfunction. The most common symptom
was vaginal dryness (45.9%), followed by decreased libido (45.2%), dyspareunia (13.3%), delayed orgasm
(11.1%), and anorgasmia (8.9%). When observed at five different time points, the frequency of symptoms
increased during chemotherapy and persisted until six months after completing treatment. Chemotherapy
duration of >120 days was associated with a higher probability of vaginal dryness (p=0.012) and decreased
libido (p=0.033). Spouse age ≥55 years old and body mass index (BMI) ≥23 kg/m2 were associated with a
reduced probability of decreased libido (p=0.033 and 0.025, respectively). The presence of comorbidity was
associated with a reduced probability of delayed orgasm (p=0.034).
Conclusions
A significant proportion of patients with breast cancer had sexual dysfunction following chemotherapy.
Vaginal dryness, decreased libido, and dyspareunia were the commonest symptoms observed. Duration of
chemotherapy, spouse age, BMI, and comorbidity were associated with the risk of sexual dysfunction
occurrence |
